Efficacy and Future Role of Ibrutinib in CLL and MCL

BCR Inhibitors in CLL and LymphomaПодробнее

Ibrutinib's role in CLL treatment and future outlooksПодробнее

MCL: Long-Term Safety/Efficacy Data With IbrutinibПодробнее

Dr. Goy on Efficacy With Ibrutinib in MCLПодробнее

Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCLПодробнее

CLL: Chemotherapy and Ibrutinib based regimensПодробнее

Dr. Richard R. Furman on the Efficacy of Ibrutinib in CLLПодробнее

Interim Data of Cirmtuzumab and Ibrutinib Show Efficacy in MCL and CLLПодробнее

Ibrutinib combined with TGR-1202 in CLL and mantle cell lymphoma (MCL): preliminary resultsПодробнее

Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCLПодробнее

Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLLПодробнее

Umbralisib with ibrutinib in patients with R/R CLL or MCLПодробнее

Martin Dreyling, MD: Efficacy of First-Line Ibrutinib in MCLПодробнее

Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLLПодробнее

Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutationПодробнее

Dr. Goy on Acalabrutinib Versus Ibrutinib in MCLПодробнее

BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our PatientsПодробнее

Dr. Chavez on Ongoing Efficacy and Challenges With Ibrutinib in CLLПодробнее

Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLLПодробнее

The future of fixed-duration therapy in CLLПодробнее